surmount-1 trial tirzepatide weight loss nondiabetic — 22.5% Dose-Dependent Efficacy and Safety of
Description
Hepatic impairment Mild to moderate hepatic impairment does not require dose adjustments
Units depend on your vials concentration (mg/mL), so always use the number on your pharmacy label
Breastfeeding For women considering GLP-1 medications while breastfeeding, our guide on taking GLP-1 while breastfeeding covers the current safety data and recommendations for both medications
Strengths This meta-analysis offers several important strengths
Key Takeaways Switching between semaglutide and tirzepatide is not a dose-for-dose conversion, and no FDA-approved equivalency exists
